Telix Pharmaceuticals - Prostate programmes boosted
Telix Pharmaceuticals has added significant value by acquiring ANMI, the developer of its TLX591-CDx prostate cancer imaging kit and underlying ‘cold kit’ technology. It also announced plans to accelerate its TLX591 prostate cancer therapeutic into Phase III, based on a third-party review of clinical data that formed part of the Atlab acquisition in September. Following the ANMI acquisition we increase our valuation to A$380m (vs A$303m) or A$1.74 per share (vs A$1.43 per share). FDA agreement to the TLX591 Phase III design would likely prompt a further valuation uplift.Telix Pharmaceuticals Ltd. Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.